在癌症免疫周期中发挥作用的众多因素提供了广泛的潜在治疗目标。
这些突出因素治疗作用，目前正在临床前或临床评估的。
关键的亮点包括疫苗可主要促进周期第2步，抗CTLA 4主要可促进周期第3步，抗PD-L1或抗PD-1抗体可主要促进周期步骤 7
虽然还没有发展成为免疫疗法，但化疗、放射治疗和靶向治疗主要可以促进周期第一步，而VEGF抑制剂可以潜在地促进T细胞向肿瘤的浸润-周期步骤5
The numerous factors that come into play in the Cancer-Immunity Cycle provide a wide range of potential therapeutic targets. This figure highlights examples of some of the therapies currently under preclinical or clinical evaluation. Key highlights include that vaccines can primarily promote cycle step 2, anti-CTLA4 can primarily promote cycle step 3, and anti-PD-L1 or anti-PD-1 antibodies can primarily promote cycle step 7. Although not developed as immunotherapies, chemotherapy, radiation therapy, and targeted therapies can primarily promote cycle step 1, and inhibitors of VEGF can potentially promote T cell infiltration into tumors—cycle step 5. Abbreviations are as follows: GM-CSF, granulocyte macrophage colony-stimulating factor; CARs, chimeric antigen receptors.
|
|
